Cardiovascular Protection and Liver Support

Evidence Review

Ren et al. 2019 — Comprehensive Cardiovascular Review

This review in Frontiers in Pharmacology [1] synthesized the clinical and pharmacological evidence for Danshen across cardiovascular disease, drawing from human trials, meta-analyses, and mechanistic studies.

Key cardiovascular findings:

Angina: Compound Danshen Dropping Pills (CDDP), a standardized pharmaceutical formulation, has been tested against nitroglycerin and conventional cardiac therapy in multiple Chinese RCTs. Meta-analysis of these trials showed CDDP produced comparable anti-anginal efficacy with fewer adverse events (headache, flushing) than nitroglycerin. Effect size for angina episode reduction: CDDP groups typically showed 70–90% responder rates vs 60–75% in control groups.

Heart failure: In adjunct trials adding Danshen to conventional heart failure treatment, the Danshen groups showed significant improvements in left ventricular ejection fraction (LVEF), reduced brain natriuretic peptide (BNP — a biomarker of cardiac stress), and better exercise tolerance scores. These trials generally ran 4–12 weeks and showed consistent benefit signals.

Atherosclerosis biomarkers: In human trials, Danshen supplementation consistently reduced LDL oxidation, decreased carotid intima-media thickness (a structural marker of atherosclerosis), and lowered inflammatory markers including CRP and fibrinogen compared to control groups.

The authors note that most large trials are from Chinese clinical settings and use combination formulas, making it difficult to attribute all effects specifically to Danshen alone. The underlying mechanistic evidence is, however, robust and consistent with clinical observations.

Yin et al. 2013 — Cardioprotection Against Ischemia-Reperfusion Injury

This study in the European Journal of Pharmacology [2] investigated the mechanism by which danshensu (a salvianolic acid-family compound) protects heart cells during ischemia-reperfusion (I/R) injury — the sequence of events during a heart attack when blood flow stops then resumes, paradoxically causing additional damage through oxidative burst.

In H9c2 cardiomyocytes subjected to I/R injury:

• Danshensu pretreatment significantly increased cell viability (approximately 40% improvement vs. untreated I/R cells at tested concentrations)
• Akt phosphorylation increased significantly, activating pro-survival cellular signaling
• ERK1/2 phosphorylation was enhanced, further suppressing apoptosis
• When Akt inhibitors were added alongside danshensu, the protective effect was largely abolished — confirming Akt is the primary survival pathway involved
• Cytochrome c release from mitochondria (a key apoptosis trigger) was reduced in danshensu-treated cells

The study establishes a clear cellular mechanism: danshensu activates Akt and ERK1/2 survival kinases, suppressing the apoptotic cascade in cardiac cells deprived of oxygen. This mechanism is relevant to heart attack injury prevention and post-infarction recovery.

Wang et al. 2011 — Salvianolic Acid vs. Tanshinone Signaling Comparison

This Journal of Ethnopharmacology study [3] addressed an important mechanistic question: Danshen's two active families (salvianolic acids and tanshinones) both protect the heart — but through the same pathways, or different ones?

Using an acute myocardial infarction model with both in vitro and in vivo components:

• Salvianolic acid acted primarily through the PI3K/Akt pathway, increasing Bcl-2 (anti-apoptotic) expression and reducing Bax (pro-apoptotic) expression, while also activating the Nrf2 antioxidant defense pathway
• Tanshinone IIA acted primarily through HIF-1α/VEGF signaling, promoting angiogenesis (new blood vessel formation) and improving microcirculation in ischemic tissue
• When tested in combination, the two families showed additive cardioprotection beyond either alone — suggesting the traditional whole-root preparation capturing both fractions may be superior to isolated compounds

This mechanistic differentiation is practically significant: salvianolic acids appear most important for acute ischemic protection and antioxidant defense, while tanshinones contribute more to long-term vascular repair and remodeling.

Wu et al. 2020 — Vascular Endothelial Protection

This comprehensive review in Oxidative Medicine and Cellular Longevity [4] focused specifically on salvianolic acid's effects on the vascular endothelium — the single-cell-thick lining of every blood vessel that controls tone, inflammation, permeability, and coagulation.

Key mechanistic findings:

• Nitric oxide restoration: salvianolic acid B significantly increased eNOS (endothelial nitric oxide synthase) expression and activity, restoring NO availability in conditions where oxidative stress had quenched it. NO is essential for vasodilation and preventing platelet adhesion.
• Oxidative stress protection: Sal B directly scavenges superoxide, hydrogen peroxide, and peroxynitrite, with measured antioxidant capacity exceeding that of resveratrol in direct comparisons
• ICAM-1 and VCAM-1 suppression: salvianolic acids reduced expression of these adhesion molecules that recruit immune cells to inflamed arterial walls, a key step in atherosclerotic plaque initiation
• Anti-thrombotic effects: inhibited thromboxane A2 synthesis and platelet aggregation through cyclooxygenase-independent mechanisms, complementing the Akt-mediated pathways

The review also noted that Sal B crosses the blood-brain barrier and shows neuroprotective effects in cerebral ischemia models — extending the cardiovascular protection into cerebrovascular territory, which is relevant given that many patients with heart disease face stroke risk.

Liu et al. 2022 — Danshen in Non-Alcoholic Fatty Liver Disease

This Frontiers in Cardiovascular Medicine review [5] addressed Danshen's increasingly recognized role in liver metabolic disease, particularly NAFLD — now affecting an estimated 25% of adults globally and strongly linked to cardiovascular risk.

Evidence across experimental and early clinical studies showed:

• Tanshinone IIA reduced hepatic lipid accumulation in NAFLD models by activating AMPK (the energy-sensing enzyme that promotes fat oxidation) and inhibiting SREBP-1c (a transcription factor driving fat synthesis in the liver)
• Salvianolic acid B reduced hepatic steatosis score by suppressing inflammatory NF-κB signaling and reducing IL-6 and TNF-α in liver tissue
• Danshen preparations improved the NAFLD Activity Score (NAS) in animal models — a composite score incorporating steatosis, inflammation, and ballooning injury
• In small human studies, liver enzyme levels (ALT, AST) improved significantly with Danshen supplementation versus baseline
• Fibrosis markers (TGF-β1, hydroxyproline content) were reduced, suggesting a potential role in slowing progression to cirrhosis

The cardiovascular connection is important here: NAFLD is now recognized as a direct risk factor for cardiovascular disease beyond the metabolic syndrome components it tracks with, and Danshen's simultaneous action on both the liver and vasculature may be particularly valuable in metabolic syndrome presentations.

Evidence Strength Summary

Cardiovascular (angina, heart failure): Moderate-to-strong — multiple Chinese RCTs and meta-analyses support efficacy comparable to conventional treatment in angina; consistent signal in heart failure adjunct trials. Confidence: moderate-to-high for standardized preparations.

Anti-ischemic / cardioprotective mechanisms: Strong — robust and consistent mechanistic evidence across multiple signaling pathways (Akt, ERK1/2, NF-κB, HIF-1α), confirmed in multiple in vitro and animal models. Confidence: high for mechanistic basis.

Atherosclerosis prevention: Moderate — consistent effect on biomarkers (LDL oxidation, carotid IMT, CRP) in human trials, with strong supporting mechanistic data. Confidence: moderate.

Liver protection / NAFLD: Moderate — strong mechanistic and animal evidence, small human studies; large RCTs needed. Confidence: moderate.

Interactions: High confidence — warfarin interaction is clinically established and well documented. This is not a theoretical risk.